AB Stock Overview
AB Science S.A., a pharmaceutical company, engages in the research, development, and marketing of protein kinase inhibitors for use in human and veterinary medicines.
| Snowflake Score | |
|---|---|
| Valuation | 0/6 |
| Future Growth | 1/6 |
| Past Performance | 0/6 |
| Financial Health | 0/6 |
| Dividends | 0/6 |
Rewards
Risk Analysis
+ 1 more risk
AB Science S.A. Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | €1.99 |
| 52 Week High | €6.54 |
| 52 Week Low | €1.55 |
| Beta | 1.06 |
| 1 Month Change | -18.94% |
| 3 Month Change | -37.32% |
| 1 Year Change | -68.66% |
| 3 Year Change | -87.41% |
| 5 Year Change | -56.74% |
| Change since IPO | -84.31% |
Recent News & Updates
Shareholder Returns
| AB | FR Pharmaceuticals | FR Market | |
|---|---|---|---|
| 7D | -11.2% | -1.6% | -0.03% |
| 1Y | -68.7% | -14.5% | 1.8% |
Return vs Industry: AB underperformed the French Pharmaceuticals industry which returned -14% over the past year.
Return vs Market: AB underperformed the French Market which returned 1.7% over the past year.
Price Volatility
| AB volatility | |
|---|---|
| AB Average Weekly Movement | 13.6% |
| Pharmaceuticals Industry Average Movement | 3.5% |
| Market Average Movement | 4.4% |
| 10% most volatile stocks in FR Market | 9.7% |
| 10% least volatile stocks in FR Market | 2.3% |
Stable Share Price: AB's share price has been volatile over the past 3 months.
Volatility Over Time: AB's weekly volatility (14%) has been stable over the past year, but is still higher than 75% of French stocks.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| 2001 | 89 | Alain Moussy | www.ab-science.com |
AB Science S.A., a pharmaceutical company, engages in the research, development, and marketing of protein kinase inhibitors for use in human and veterinary medicines. Its lead compound is the masitinib, a tyrosine kinase inhibitor that is in Phase III clinical trials for the treatment of prostate and pancreatic cancer, amyotrophic lateral sclerosis, multiple sclerosis, Alzheimer's, severe asthma, and mastocytosis diseases, as well as in Phase II clinical trial to treat Covid-19. The company is also developing AB8939, a synthetic microtubule destabiliser for haematology indications.
AB Science S.A. Fundamentals Summary
| AB fundamental statistics | |
|---|---|
| Market cap | €101.62m |
| Earnings (TTM) | -€16.88m |
| Revenue (TTM) | €777.00k |
130.8x
P/S Ratio-6.0x
P/E RatioIs AB overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| AB income statement (TTM) | |
|---|---|
| Revenue | €777.00k |
| Cost of Revenue | €92.00k |
| Gross Profit | €685.00k |
| Other Expenses | €17.57m |
| Earnings | -€16.88m |
Last Reported Earnings
Jun 30, 2023
Next Earnings Date
Apr 30, 2024
| Earnings per share (EPS) | -0.33 |
| Gross Margin | 88.16% |
| Net Profit Margin | -2,173.10% |
| Debt/Equity Ratio | -97.2% |
How did AB perform over the long term?
See historical performance and comparison